LUNESTA

This brand name is authorized in United States. It is also authorized in Canada, Japan.

Active ingredients

The drug LUNESTA contains one active pharmaceutical ingredient (API):

1	Eszopiclone UNII UZX80K71OE - ESZOPICLONE
	Eszopiclone is indicated for the treatment of insomnia. The mechanism of action of eszopiclone as a hypnotic is unclear; however, its effect could be related to its interaction with GABA-receptor complexes at binding domains located close to or allosterically coupled to benzodiazepine receptors.
	Read more about Eszopiclone

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
LUNESTA Coated tablet	MPI, US: SPL/PLR	FDA, National Drug Code (US)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
N05CF04	Eszopiclone	N Nervous system → N05 Psycholeptics → N05C Hypnotics and sedatives → N05CF Benzodiazepine related drugs
Discover more medicines within N05CF04

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
CA	Health Products and Food Branch	02453207, 02453215, 02453223
JP	医薬品医療機器総合機構	1129010F1028, 1129010F2024, 1129010F3020
US	FDA, National Drug Code	55289-014, 63402-190, 63402-191, 63402-193, 80425-0062, 80425-0063, 80425-0064, 80425-0065, 80425-0066, 80425-0067